Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is some evidence that statins may have a protective and symptomatic benefit in Alzheimer disease (AD). The LEADe study is a randomized controlled trial (RCT) evaluating the efficacy and safety of atorvastatin in patients with mild to moderate AD. METHODS: This was an international, multicenter, double-blind, randomized, parallel-group study. Subjects had mild to moderate probable AD (Mini-Mental State Examination score 13-25), were aged 50-90 years, and were taking donepezil 10 mg daily for > or 3 months prior to screening. Entry low-density lipoprotein cholesterol levels (LDL-C) were > 95 and < 195 mg/dL. Patients were randomized to atorvastatin 80 mg/day or placebo for 72 weeks followed by a double-blind, 8-week atorvastatin withdrawal phase. Coprimary endpoints were changes in cognition (Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog]) and global function (Alzheimer's Disease Cooperative Study Clinical Global Impression of Change [ADCS-CGIC]) at 72 weeks. RESULTS: A total of 640 patients were randomized in the study. There were no significant differences in the coprimary endpoints of ADAS-cog or ADCS-CGIC or the secondary endpoints. Atorvastatin was generally well-tolerated. CONCLUSIONS: In this large-scale randomized controlled trial evaluating statin therapy as a treatment for mild to moderate Alzheimer disease, atorvastatin was not associated with significant clinical benefit over 72 weeks. This treatment was generally well-tolerated without unexpected adverse events. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that intensive lipid lowering with atorvastatin 80 mg/day in patients with mild to moderate probable Alzheimer disease (aged 50-90), taking donepezil, with low-density lipoprotein cholesterol levels between 95 and 195 mg/dL over 72 weeks does not benefit cognition (as measured by Alzheimer's Disease Assessment Scale-Cognitive Subscale) (p = 0.26) or global function (as measured by Alzheimer's Disease Cooperative Study Clinical Global Impression of Change) (p = 0.73) compared with placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some observational studies have suggested a beneficial effect of aspirin on cognition,465,466 although this was not confirmed in others.467,468”
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
A nonparametric method for automatic correction of intensity nonuniformity in MRI data
Sled, J. G., Zijdenbos, A. P., & Evans, A. C. (1998) · IEEE Transactions on Medical Imaging · doi:10.1109/42.668698 · Cited by 4,731
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationA new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Research works printed but not linked: 3
- Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A. Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:63–70.
- Austen B, Frears E, Davies H. Cholesterol upregulates production of A[beta] 1-40 and 1-42 in transfected cells. Neurobiol Aging 2000;21:254.
- Hoglund K, Wallin A, Blennow K. Effect of statins on beta-amyloid metabolism in humans: potential importance for the development of senile plaques in Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:87–92.
Cited by
Items 301–400 of 443
A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease
Rajabian, A., McCloskey, A. P., Jamialahmadi, T., Moallem, S. A., & Sahebkar, A. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0005 · Cited by 7
Sung, E. M., & Saver, J. L. (2024) · Stroke · doi:10.1161/strokeaha.123.044071 · Cited by 8
Hierarchical Bayesian cognitive processing models to analyze clinical trial data
Shankle, W. R., Hara, J., Mangrola, T., Hendrix, S. B., Alva, G., & Lee, M. D. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.01.016 · Cited by 7
Lipid Control and Beyond: Current and Future Indications for Statin Therapy in Stroke
Yaghi, S. R., & Elkind, M. S. V. (2016) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-016-0448-8 · Cited by 7
Sabeel, S., Motaung, B., Ozturk, M., Mukasa, S. L., Kengne, A. P., Blom, D. J., Sliwa, K. S., Nepolo, E., Günther, G., Wilkinson, R. J., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-039034 · Cited by 9
Review of the Protective Effects of Statins on Cognition
Chadha, B., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000359 · Cited by 8
Chau, S. A., Liu, C. S., Ruthirakuhan, M. T., Lanctôt, K. L., & Herrmann, N. (2017) · Mental health and illness worldwide · doi:10.1007/978-981-10-2414-6_20 · Cited by 7
Luckhoff, H. K., Kidd, M., van Rensburg, S. J., van Velden, D. P., & Kotze, M. J. (2015) · Metabolic Brain Disease · doi:10.1007/s11011-015-9737-2 · Cited by 8
Drug Development for Alzheimer's Disease: Recent Progress
Ji, W., & Ha, I. (2010) · Experimental Neurobiology · doi:10.5607/en.2010.19.3.120 · Cited by 7
FLAXSEEDS AND AJWAIN FOR PRIMARY HYPERLIPIDEMIA
Jalbani, G. A., HAKRO, D. S., Murad, S., Niaz, K., Qudoos, A., Moeen-Ud-Din, H., & Fatima, A. (2016) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v6i2.1203 · Cited by 7
Fillit, H. M. (2010) · Evidence-Based Mental Health · doi:10.1136/ebmh1069 · Cited by 7
Pollen, D. A., Baker, S. P., Hinerfeld, D. A., Swearer, J. M., Evans, B. A., Evans, J. E., Caselli, R. J., Rogaeva, E. A., George‐Hyslop, P. S., & Moonis, M. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt55 · Cited by 8
Clinical trial efforts in Alzheimer disease: Why test statins?
Arvanitakis, Z., & Knopman, D. S. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6479a · Cited by 8
Statins for the primary prevention of venous thromboembolism
Wang, Z., Zhang, P., Tian, J., Zhang, P., Yang, K., & Li, L. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014769.pub2 · Cited by 12
How Statins Could Be Evaluated Successfully in Clinical Trials for Alzheimer’s Disease?
Burgos, J. S., Bénavidès, J., Douillet, P., Velasco, J., & Valdivieso, F. (2012) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317512442998 · Cited by 6
Pawar, S., Pingale, P., Garkal, A., Osmani, R. A. M., Gajbhiye, K. R., Kulkarni, M., Pardeshi, K., Mehta, T. A., & Rajput, A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131139 · Cited by 6
Tratamento da doença de Alzheimer
de Assis, F., do Vale, C., Neto, Y. C., Bertolucci, P. H. F., Machado, J. C., da Silva, D. J., Allam, N., & Balthazar, M. L. F. (2011) · Dementia & Neuropsychologia · Cited by 22
Systematic Review of Atorvastatin for the Treatment of Alzheimer's Disease
(2012) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-5374.2012.17.010 · Cited by 6
Potential role of Drug Repositioning Strategy (DRS) for management of tauopathy
Zaki, M. O., Elsherbiny, D. A., Salama, M., & Azab, S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120267 · Cited by 7
Cardiovascular disease prevention and the rise in dementia
Thompson, G. R. (2011) · QJM · doi:10.1093/qjmed/hcr181 · Cited by 6
FEATURES OF NOSOCOMIAL KLEBSIELLA PNEUMONIAE POPULATION
Kuzmenko, S. A., BREZHNEVA, N. I., GONCHAROV, A. E., & Tutelyan, A. V. (2019) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2019-4-2-58-65 · Cited by 6
GEOGRAPHIC INFORMATION SYSTEM ANALYSIS OF RABIES SPREAD IN ISLAND FOREST-STEPPE OF EAST SIBERIA
Дмитриевич, З. И., Botvinkin, A. D., Goryaev, D. V., Region, F. S. O. S. F. C. R. P. A. H. W. I. K., DEMCHIN, P. M., DMITRIEVA, G. M., Region, F. S. O. S. F. C. R. P. A. H. W. I. K., ZAYKOVA, T. A., LUTSENKO, G. V., ROMANOVA, T. G., et al. (2019) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2019-4-2-48-57 · Cited by 7
Solmaz, V., Atasoy, Ö., & Erbaş, O. (2020) · Neurological Research · doi:10.1080/01616412.2020.1747718 · Cited by 7
The Effects of Lower BP Goals on Cognitive Function in the Elderly
Zamora, Z., & Williamson, J. D. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01312-2 · Cited by 6
Lipid Metabolism and Statin Therapy in Neurodegenerative Diseases: An Endocrine View
Sarno, A. D., Romano, F., Arianna, R., Serpico, D., Lavorgna, M., Savastano, S., Colao, A., & Somma, C. D. (2025) · Metabolites · doi:10.3390/metabo15040282 · Cited by 6
Lifestyle Factors in the Prevention of Dementia: A Life Course Perspective
Qiu, C. (2014) · International perspectives on aging · doi:10.1007/978-3-319-06650-9_11 · Cited by 5
Sang, X., Chen, W., Hou, X., Wang, C., Zhang, D., & Hou, L.-J. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240270 · Cited by 5
“27 Similarly, a randomized, double-blind, placebo-controlled trial involving 406 patients aged 50 years or older with mild to moderate probable AD found that simvastatin treatment (20 mg/day for 6 months followed by 40 mg/day for subsequent 12 months) did not significantly improve clinical…”
Sabbagh, M. N., Malek‐Ahmadi, M. H., Levenson, I., & Sparks, D. L. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121015 · Cited by 5
Self-citationPuerto, A. M. H., Russo, C., & Fregni, F. (2018) · Neuromethods · doi:10.1007/978-1-4939-7880-9_9 · Cited by 10
Chau, S. A., Liu, C. S., Ruthirakuhan, M. T., Lanctôt, K. L., & Herrmann, N. (2016) · Mental health and illness worldwide · doi:10.1007/978-981-10-0370-7_20-1 · Cited by 5
“Another PPARγ agonist, pioglitazone, with potentially greater ability to cross the blood-brain barrier is currently being investigated in a phase 3 trial of cognitively healthy elderly at risk of developing MCI due to AD (TOMORROW, NCT01931566) with an extension BACE β-secretase, MCI mild cognitive impairment, AD Alzh…”
BackgroundInfluentialPhelix, C. F., LeBaron, R. G., Roberson, D. J., Villanueva, R. E., Villareal, G., Rahimi, O. B., Siedlak, S. L., Zhu, X., & Perry, G. L. (2011) · IEEE ... International Conference on Data Mining workshops · doi:10.1109/icdmw.2011.98 · Cited by 5
Emerging Therapeutic Strategies in Alzheimer's Disease
Chiba, T. (2013) · InTech eBooks · doi:10.5772/55293 · Cited by 5
Zhang, H., Zhou, Z., Gu, J., Lin, Y., Yan, Y., Chen, X., Fan, M., & Huang, Y. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111282 · Cited by 4
Statin Use, Ageing, and Cognition: A Review
Stephenson, N. E., & Crowe, S. F. (2016) · Australian Psychologist · doi:10.1111/ap.12116 · Cited by 4
Alzheimer’s Disease: Treatment Today and Tomorrow
Gorthi, S. P., & Gupta, D. (2023) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_254_23 · Cited by 5
Lessons Learned from Major Clinical Trials Conducted Over the Past Decades
Schüler, P., Siegfried, K., & Hüll, M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-411464-7.00006-7 · Cited by 4
Maladie d’Alzheimer et facteurs de risque vasculaire
Hanon, O., & Duron, E. (2011) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2011.03.004 · Cited by 6
Cognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_139-1 · Cited by 4
Cholesterol-modifying strategies for Alzheimer disease: promise or fallacy?
Azarfar, K., Decourt, B., Camacho, B. S., Lawrence, J. J., Omondi, T. R., & Sabbagh, M. N. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2483928 · Cited by 3
Shah, F. A., Qadir, H., Khan, J., & Faheem, M. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.03.064 · Cited by 4
Simvastatin markedly alters locomotor behavior parameters and induces mortality in planarians
Feix, J., Solek, C. C., Carus, K. M., Pedott, V. D. A., Cichota, L. C., Gonçalves, I. L., & Amaral, A. U. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178112 · Cited by 3
Petek, B., Mo, M., Xu, H., Norgren, J., Hoang, M. T., Villa‐Lopez, M., Häbel, H., Kele, J., Naia, L., Maioli, S., et al. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251385903 · Cited by 3
Zhang, L., Zhang, L., Zhao, J., Zhang, W. Y., & Zhang, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05424-0 · Cited by 3
Choi, M., Zimmerman, S. C., Jiang, C., Wang, J., Swinnerton, K. N., Hoffmann, T. J., Oni‐Orisan, A., Ferguson, E. L., Meyers, T. J., Choudhary, V., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14627 · Cited by 3
MORPHOLOGICAL AND CHEMICAL CHARACTERIZATION OF MAGNESIUM PHOSPHATE AND CALCIUM PHOSPHATE BIONS
Shishkova, D. K., Glushkova, T. V., Ефимова, О. С., Попова, А. Н., Malysheva, V. Y., Павлович, К. Р., Ismagilov, Z. R., GUTAKOVSKY, A. K., Zhivodkov, Y. A., Kozhukhov, A. S., et al. (2019) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2019-4-2-6-16 · Cited by 3
POPULATION-GENETIC RESEARCH OF THE VDR GENE POLYMORPHISM
Volkov, A. N., & Владимировна, Ц. Е. (2019) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2019-4-2-72-77 · Cited by 3
Cognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_139 · Cited by 4
Statin is associated with higher cortical thickness in early Alzheimer's disease
Zheng, Y., Gu, H., & Kong, Y. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112698 · Cited by 5
Therapeutics of Alzheimer’s Disease
Herrera-Rivero, M., & Emiliano, G. (2011) · InTech eBooks · doi:10.5772/27990 · Cited by 3
Vascular cognitive impairment and Alzheimer's disease: Is there a relationship between them?
Tabeeva, G. R., & Kiryanova, E. A. (2019) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2019-3-110-115 · Cited by 3
Can Statins Prevent Dementia in Older Adults?
Haan, M. N. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02907.x · Cited by 3
“At the same time, several controlled randomized trials of statin therapy have reported no benefits for progression in AD from treatment.(14,15) Two older trials,(16,17) using pravastatin and simvastatin, respectively, in patients with substantial heart disease found no effect of statin treatment on cognitive outcomes.”
BackgroundJasmin, S. B. (2011) · eScholarship@McGill (McGill) · doi:10.82308/52384 · Cited by 4
Highlight dementia risk to reduce CVD
Mearns, B. M., & Fuster, V. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.37 · Cited by 3
Yu, L., Xu, F., & Gao, L. (2017) · arXiv (Cornell University) · doi:10.48550/arxiv.1707.00954 · Cited by 3
“…(Boolell et al., 1996), Amphotericin B (originally designed for serious systemic fungal infections; now indicated for acute promyelocytic leukemia)(Kleinotiene et al., 2013) and Lipitor (originally designed for cardiovascular disease; now indicated for Alzheimer's) (Feldman et al., 2010).”
BackgroundThe emerging role of CETP inhibition in the prevention of Alzheimer's disease
Davidson, M. H., Hsieh, A., Kleer, M. D., Szarek, M. J., Scheltens, P., Vijverberg, E. G. B., Johnson, A. J., Ditmarsch, M., & Kastelein, J. J. P. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101442 · Cited by 2
“Simvastatin was tested in the CLASP-AD trial, and atorvastatin in the LEADe study, both involving patients with mild to moderate AD, yet neither demonstrated cognitive benefits [35,36].”
Novak, D. A., Saleem, N., Gerhardt, P. C., Maestas, D., Kejriwal, N., Vaezazizi, E., Murray, I., & Al-Khoury, L. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261424220 · Cited by 2
Drug Treatments for Alzheimer’s Disease: Hopes and Challenges
Braidy, N., Poljak, A., Jayasena, T., & Sachdev, P. S. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_141 · Cited by 2
Dementia and management of vascular cognitive impairment
Godefroy, O. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139058988.031 · Cited by 2
Alzheimersche Demenz, Cholesterin und Statine: Berührungspunkte wichtiger Stoffwechselwege
Silva, T., Teixeira, J., Remião, F., & Borges, F. (2012) · Angewandte Chemie · doi:10.1002/ange.201204964 · Cited by 2
Potential Therapeutic Effects of Statins in Alzheimer’s Disease
Mancuso, C., Head, E., Barone, E., Perluigi, M., Preziosi, P., & Butterfield, D. A. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_171 · Cited by 2
Cholesterol Levels and Cognitive Impairments
Moreira, E. L. G., de Oliveira, J., Prediger, R. D., Farina, M., & Bem, A. F. D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407824-6.00068-9 · Cited by 3
Ibuprofen in Prevention of Neurodegenerative Diseases
Rainsford, K. D. (2015) · Wiley eBooks · doi:10.1002/9781118743614.ch14 · Cited by 3
THE ROLE OF STATINS IN ALZHEIMER'S DISEASE: A META-ANALYSIS
Gizachew, S., & Makonnen, E. (2012) · African Journal of Neurological Sciences · Cited by 3
Pressman, P., & Gottfried, J. A. (2012) · Neurology · doi:10.1212/wnl.0b013e3182604385 · Cited by 2
Alzheimer's Disease: Clinical Trials and Future Perspectives
Lee, K. S., & Suh, H. S. (2012) · 대한정신약물학회지 · Cited by 2
Fedorova, N. V., German, A. I., KOKOV, A. N., Brel, N. K., Борзалиевна, П. Т., Кашталап, В. В., Каретникова, В. Н., & Барбараш, О. Л. (2019) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2019-4-2-17-27 · Cited by 4
Kellick, K. A., & Saseen, J. J. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_11 · Cited by 2
McKenney, J. M., & Roth, E. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00021-9 · Cited by 6
OVARIAN DERMOID CYST IN A PREGNANT WOMAN
Захаров, И. С., Мозес, В. Г., Рудаева, Е. В., Елгина, С. И., VASYUTINSKAYA, Y. V., NOSKOVA, V. A., & PODUSHKO, A. A. (2019) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2019-4-2-134-138 · Cited by 1
CURRENT MANAGEMENT OF ALCOHOLIC LIVER DISEASE
Tsukanov, V. V., Vasyutin, A. V., & TONKIKH, Y. L. (2019) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2019-4-2-78-83 · Cited by 1
RISK FACTORS OF HEPATITIS B IN PATIENTS ON HEMODIALYSIS: A SYSTEMATIC REVIEW
KVASHNINA, D. V., Kovalishena, O. V., & Saperkin, N. V. (2019) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2019-4-2-107-119 · Cited by 1
An Overview of Target Specific Neuro-Protective and Neuro-Restorative Strategies
Al, A., Al, K., Al-, A., Arshaduddin, M., & Tariq, M. (2012) · InTech eBooks · doi:10.5772/34731 · Cited by 1
“On the contrary no significant clinical benefit on cognition or global functioning was shown by atorvastatin in a phase 3 clinical trial in patients with mild-to-moderate AD already taking donepezil (Feldman et al., 2010).”
BackgroundThe Role of Statins in the Prevention and Treatment of Alzheimer's Disease
Desilets, A. R., Koslowski, D. A., & Dunican, K. C. (2010) · Journal of Pharmacy Technology · doi:10.1177/875512251002600505 · Cited by 1
Vascular Cognitive Disorder: A Diagnostic and Pharmacological Treatment Updating
Russo, M. J., & Allegri, R. (2014) · Current Psychopharmacologye · doi:10.2174/2211556003666140702190144 · Cited by 1
“Conclusions are based on three small randomized trials of statins in patients with mild to moderate AD (Simons, ADCLT, LEADs) [58-60].”
BackgroundMethodNeurological diseases: Sex and gender evidence in stroke, migraine, and Alzheimer’s dementia
Aggarwal, N. T., & Dafer, R. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816569-0.00011-5 · Cited by 2
Relationship Between Cholesterol Metabolism, Apoe and Brain Volumes In Alzheimer‘s Disease
Leoni, V., & Caccia, C. (2011) · Future Neurology · doi:10.2217/fnl.11.38 · Cited by 2
“As expected, a significant reduction of serum total cholesterol and LDL-C was found, but no benefit in cognition or global functioning was found [66].”
BackgroundPotential Treatments for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00008-2 · Cited by 2
[Progress of clinical trials in Alzheimer’s disease drugs].
Peng, Y., Li, P., Li, L., Zhang, Y., Hou, W.-Z., Cui, D.-D., Li, J., Wang, L., Wang, Q., & Wang, X. (2016) · PubMed · Cited by 1
Neuroinflammation in Alzheimer's Disease Continuum
Sag, A. T., & Yemişçi, M. (2020) · Neurological Sciences and Neurophysiology · doi:10.4103/nsn.nsn_190_20 · Cited by 1
The Role of Adaptive and Innate Immunity in Alzheimer’s Disease
Holmes, C. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108539623.012 · Cited by 1
Inzitari, M., & Inzitari, D. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch65 · Cited by 1
Seux, M. (2012) · Wiley eBooks · doi:10.1002/9781119952930.ch75 · Cited by 2
Statins and Cognitive Impairment: Mechanisms, Evidence, and Research Directions
Cho, H.-J. (2025) · NeuroTrials · doi:10.65321/ntta.2025.003 · Cited by 1
Blutbasierte Mikrozirkulationsmarker bei der Alzheimer-Demenz
Knauer, K. (2010) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.12369
Euphoria in multiple sclerosis: an investigation of constructs and symptons
Duncan, A. L. (2014) · Open University of Cape Town (University of Cape Town) · Cited by 1
Cognitive Enhancers and Treatments for Alzheimer's Disease
Devanand, D. P. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch109
Simmons, C. R. (2011) · UKnowledge (University of Kentucky)
Statins and dementia: Does length of statins use matter?
Ikewaki, K. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.055
Serum lipids and gender affect trajectories of cognitive function in late life
Wellington, C. L. (2010) · Clinical Lipidology · doi:10.2217/clp.10.46
Treatment of patients with post-stroke dementia
Mackowiak, M., & Pasquier, F. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139058988.033
Associations between cardiovascular risk factors, hyper- and hypocoagulability
Rafi, S. (2011) · UvA-DARE (University of Amsterdam)
Nilsson, P. M., Román, G. C., Sellke, F. W., Seshadri, S. S., Arnett, K., Bennett, D. A., Chui, H. C., Higashida, R. T., Lindquist, R. D., Nyenhuis, D. L., et al. (2011)
Chui, H. C., Higashida, R. T., Lindquist, R. D., Nilsson, P. M., Petersen, C., Schneider, J. A., Tzourio, C., Arnett, D. K., Launer, L. J., Laurent, S., et al. (2013)
Future Pharmacological Armamentaria in Management of Alzheimer Disease
Shah, M. H., Shah, H. D., & Chaudhari, V. (2013) · National Journal of Community Medicine
Life style-related disorders and independence in old patients -Dyslipidemia-
Eto, M. (2013) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.50.176
Estatinas: efeitos pleiotrópicos. Statins: pleiotropic effects
Machado, W. M., Munhoz, A. C. M., & Fernandes, D. (2011) · Publicatio UEPG Ciencias Biologicas e da Saude · doi:10.5212/publ.biologicas.v.17i2.0008 · Cited by 2
Predictors of Dementia and Memory Decline: Lifecourse Socioeconomic Status and Diabetes
Marden, J. R. (2016) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 1
Cohen, A. D., & Aizenstein, H. J. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.04.007
Metadata
- Authors
- Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., & Breazna, A.
- Affiliations
- San Francisco General Hospital (US)
- From the Division of Neurology (H.H.F.), University of British Columbia, UBCH Clinic for Alzheimer's Disease and Related Disorders, Vancouver, Canada; Department of Neurology (R.S.D.), Baylor College of Medicine, Houston, TX; Aging Research Center (M.K.), Karolinska Institutet, Stockholm, Sweden; Ralph & Muriel Roberts Laboratory For Neurodegenerative Research (D.L.S.), Sun Health Research Institute, Sun City, AZ; San Francisco General Hospital (D.D.W.), San Francisco, CA; RICE (The Research...
- Venue
- Neurology
- Published
- 2010-03-23
- Volume
- 74
- Issue
- 12
- Pages
- 956-964
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2030025114
- Cited by
- 438
- References
- 38
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 14 · 2023: 12 · 2022: 10 · 2021: 18 · 2020: 27 · 2019: 42 · 2018: 16 · 2017: 26 · 2016: 34 · 2015: 26 · 2014: 33 · 2013: 28 · 2012: 49
- FWCI
- 32.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Pfizer
- IXICO
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- atorvastatin, Alzheimer's disease, statins, lipid lowering, donepezil, cognitive function, global function, LDL cholesterol, drug safety and efficacy
- MeSH terms
- Atorvastatin, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Heptanoic Acids, Hippocampus, Humans, Cholesterol, LDL, Magnetic Resonance Imaging, Male, Middle Aged, Organ Size, Pyrroles, Cholinergic Antagonists, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.